Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001029890 | SCV001592102 | pathogenic | Imerslund-Grasbeck syndrome | 2020-02-28 | criteria provided, single submitter | clinical testing | Loss-of-function variants in CUBN are known to be pathogenic (PMID: 15024727, 22929189). For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with CUBN-related conditions. This variant is present in population databases (rs374417889, ExAC 0.02%). This sequence change creates a premature translational stop signal (p.Arg2030*) in the CUBN gene. It is expected to result in an absent or disrupted protein product. |
Revvity Omics, |
RCV001784565 | SCV002023990 | pathogenic | not provided | 2023-06-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001784565 | SCV002032420 | pathogenic | not provided | 2024-08-05 | criteria provided, single submitter | clinical testing | Identified with a second variant in unrelated patients with kidney disease in published literature (PMID: 31613795, 35064937); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 15024727, 31613795, 22929189, 35064937) |
Fulgent Genetics, |
RCV002497349 | SCV002814305 | likely pathogenic | Imerslund-Grasbeck syndrome type 1; Proteinuria, chronic benign | 2022-05-31 | criteria provided, single submitter | clinical testing | |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV001029890 | SCV001192681 | likely pathogenic | Imerslund-Grasbeck syndrome | 2019-03-19 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003928668 | SCV004741290 | pathogenic | CUBN-related disorder | 2023-11-29 | no assertion criteria provided | clinical testing | The CUBN c.6088C>T variant is predicted to result in premature protein termination (p.Arg2030*). This variant was reported with a second CUBN variant in two patients with kidney disease; however, phase of the variants was not determined (Supp. Table 2 in Bedin et al. 2020. PubMed ID: 31613795). Of note, the c.6088C>T has been reported with the c.5428C>T (p.Arg1810*) variant in two patients in the literature, but segregation analysis was not completed to determine phase (Family 21, Supp Table 2 in Bedin et al. 2020. PubMed ID: 31613795; Case #20, Supp. Table 3 in Lu L et al 2022. PubMed ID: 35064937). At PreventionGenetics, we have observed the c.6088C>T and c.5428C>T variants to occur on the same allele (cis phase) based on parental follow up testing (internal data). This variant is reported in 0.015% of alleles in individuals of East Asian descent in gnomAD, including one homozygous individual. Nonsense variants in CUBN are expected to be pathogenic. This variant is interpreted as pathogenic. |